Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Henry Chesbrough


Open innovation, a strategy popularized by Henry Chesbrough, has taken the business world by storm. In his 2003 breakout book, Chesbrough argued — based largely on observations of the computer industry — that companies need to look beyond their walls to thrive. Gone are the days when in-house research and development (R&D) muscle alone could dominate markets . The future's giants will get the best bang for their research buck by bringing external ideas in and by letting internal ideas out. For drug discoverers, who have been battered by poor R&D returns, the promise of open innovation is appealing, even if differences between the biopharma and computer industries pose challenges. Drug companies, as a result, are increasingly talking the talk of open innovation and experimenting with academic collaborations, licensing deals, spin-outs and acquisitions. Chesbrough, a professor at the University of California in Berkeley, tells Asher Mullard about the trends and limitations of open innovation in life sciences.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mullard, A. Henry Chesbrough. Nat Rev Drug Discov 12, 338–339 (2013).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing